Targacept flushes TC-5214 program in overactive bladder
This article was originally published in Scrip
Executive Summary
Targacept will discontinue development of TC-5214 in the treatment of overactive bladder (OAB) after the drug failed in a Phase IIb clinical trial, adding to a string of failures for its pipeline of therapeutic candidates targeting the neuronal nicotinic receptor (NNR).